Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Claude Bernhart.
Journal of Cardiovascular Pharmacology | 2004
Patrick Gautier; Eric Guillemare; Laurent Djandjighian; Aline Marion; Jacques Planchenault; Claude Bernhart; Jean-Marc Herbert; Dino Nisato
SSR149744C (SSR, 2-butyl-3-{4-[3-(dibutylamino)pro-pyl]benzoyl}-1-benzofuran-5-carboxylate isopropyl fumarate), is a new non-iodinated benzofuran derivative. The aim of this study was to evaluate in vivo its electrophysiological, hemodynamic, and anti-adrenergic properties and to determine its mechanism of action using in vitro studies. In chloralose-anesthetized dogs, SSR149744C (1–10 mg/kg i.v.) prolonged the sinus cycle length, A-H interval, Wenckebach cycle length, atrial effective refractory period (ERP), and atrio-ventricular node ERP in a dose-dependent manner without change of ventricular ERP and HV, QRS, or QTc intervals. Arterial blood pressure and ventricular inotropism were slightly decreased. SSR149744C, which has no or low affinity for &agr;1 and β1 adrenergic and angiotensin II AT1 receptors, reduced isoproterenol-induced tachycardia and phenylephrine- or angiotensin II-induced hypertension in anaesthetized dogs. In guinea pig papillary muscle, SSR149744C did not modify the resting potential, action potential amplitude and duration, but reduced the dV/dt max of the depolarization phase in a frequency-dependent manner. In isolated guinea pig cardiomyocytes and transfected CHO cells, SSR149744C (0.01–30 μM) inhibited several potassium currents: IKr (IC50 ~10 μM), IKs (IC50 ~30 μM), IK(ACh) (IC50 = 0.09 μM), and IKv1.5 (IC50 = 2.7 μM), the L-type calcium current: ICa(L) (IC50 ~ 5 μM) and also the amplitude of [Ca2+]i transient and cell shortening. Therefore, SSR149744C appears to have a multifactorial mechanism of action, which combines the blockade of several ion channels with the inhibition of responses of &agr;1 and β1 adrenergic as well as AT1 receptor stimulation. Like amiodarone, SSR149744C possesses the pharmacological effects of class I, II, III, and IV antiarrhythmic agents, which may confer upon this new drug a strong antiarrhythmic potential without ventricular proarrhythmia and iodine-related amiodarone-like side-effects.
Archive | 1991
Claude Bernhart; Jean-Claude Breliere; Jacques Clement; Dino Nisato; Pierre Perreault; Claude Muneaux; Yvette Muneaux
Journal of Medicinal Chemistry | 1993
Claude Bernhart; Perreaut Pm; Ferrari Bp; Muneaux Ya; Assens Jl; Clément J; Haudricourt F; Muneaux Cf; Taillades Je; Vignal Ma
Archive | 1991
Claude Bernhart; Jean-Claude Breliere; Jacques Clement; Dino Nisato; Pierre Perreaut
Archive | 1991
Claude Bernhart; Jean-Claude Breliere; Jacques Clement; Dino Nisato; Pierre Perreaut
Archive | 1994
Claude Bernhart; Jean-Claude Breliere; Jacques Clement; Dino Nisato; Pierre Perreault; Claude Muneaux; Yvette Muneaux
Archive | 1993
Claude Bernhart; Jean-Claude Breliere; Jacques Clement; Dino Nisato; Pierre Perreault; Claude Muneaux; Yvette Muneaux
Journal of Medicinal Chemistry | 1983
Claude Bernhart; Christian Condamine; Henri Demarne; Roméo Roncucci; Jean Pierre Gagnol; Patrick J. Gautier; Martine Serre
Archive | 1992
Claude Bernhart; Bernard Ferrari; Pierre Perreaut
Archive | 2001
Jean-Louis Assens; Claude Bernhart; Frederique Cabanel-Haudricourt; Dino Nisato